Fluoroquinolone-resistant Streptococcus pneumoniae in Spain: activities of garenoxacin against clinical isolates including strains with altered topoisomerases

Antimicrob Agents Chemother. 2003 Aug;47(8):2692-5. doi: 10.1128/AAC.47.8.2692-2695.2003.

Abstract

The activity of garenoxacin was assessed against 412 Streptococcus pneumoniae isolates (49.3% from the adult population). Overall penicillin, erythromycin, and ciprofloxacin (MIC, >/=4 micro g/ml) resistance was 51.7, 35.4, and 1.5%, respectively. For all isolates, the garenoxacin MIC was </=1 micro g/ml. Amino acid replacements in GryA (Ser81-->Phe or Tyr), ParC (Ser79-->Phe or Tyr; Asp83-->Gly; Lys137-->Asn), and ParE (Ile460-->Val; Asp435-->Asn), alone or in combination, were ascribed to the reduced garenoxacin susceptibility (MIC range, 0.5 to 1 micro g/ml) found in four isolates. The low impact of these mutations on garenoxacin activity envisages the possible coverage of S. pneumoniae populations resistant to preexisting quinolones.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Anti-Infective Agents / pharmacology*
  • DNA Gyrase / drug effects
  • DNA Gyrase / genetics
  • DNA Topoisomerases / metabolism*
  • DNA, Bacterial / genetics
  • Drug Resistance, Bacterial
  • Fluoroquinolones*
  • Genes, Bacterial / genetics
  • Humans
  • Indoles / pharmacology*
  • Methyltransferases / genetics
  • Microbial Sensitivity Tests
  • Pneumococcal Infections / epidemiology
  • Pneumococcal Infections / microbiology*
  • Prospective Studies
  • Quinolones / pharmacology*
  • Reverse Transcriptase Polymerase Chain Reaction
  • Spain / epidemiology
  • Streptococcus pneumoniae / drug effects*
  • Streptococcus pneumoniae / enzymology
  • Streptococcus pneumoniae / genetics

Substances

  • Anti-Infective Agents
  • DNA, Bacterial
  • Fluoroquinolones
  • Indoles
  • Quinolones
  • Methyltransferases
  • rRNA (adenosine-O-2'-)methyltransferase
  • DNA Topoisomerases
  • DNA Gyrase
  • garenoxacin